Victory Capital Management Inc. Increases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Victory Capital Management Inc. raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 92,891 shares of the biopharmaceutical company’s stock after buying an additional 3,977 shares during the period. Victory Capital Management Inc. owned approximately 0.09% of Regeneron Pharmaceuticals worth $81,585,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Eudaimonia Advisors LLC grew its stake in Regeneron Pharmaceuticals by 1.2% during the 4th quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company’s stock worth $803,000 after purchasing an additional 11 shares in the last quarter. Drive Wealth Management LLC grew its position in shares of Regeneron Pharmaceuticals by 4.0% during the fourth quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 12 shares in the last quarter. MCF Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 12 shares during the period. LCM Capital Management Inc grew its holdings in Regeneron Pharmaceuticals by 2.5% during the 4th quarter. LCM Capital Management Inc now owns 486 shares of the biopharmaceutical company’s stock worth $427,000 after acquiring an additional 12 shares in the last quarter. Finally, Sutton Wealth Advisors Inc. increased its position in shares of Regeneron Pharmaceuticals by 38.2% in the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 13 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 2.1 %

Shares of NASDAQ REGN opened at $957.00 on Friday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $684.80 and a 52-week high of $998.33. The company has a quick ratio of 4.94, a current ratio of 6.40 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $105.04 billion, a P/E ratio of 28.27, a PEG ratio of 2.69 and a beta of 0.17. The stock’s 50 day moving average price is $944.24 and its two-hundred day moving average price is $895.54.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. The company had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The firm’s revenue was up .6% compared to the same quarter last year. During the same period in the prior year, the company earned $10.96 earnings per share. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.86 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 854 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $979.25, for a total value of $836,279.50. Following the sale, the director now directly owns 1,382 shares in the company, valued at $1,353,323.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $982.05, for a total value of $98,205.00. Following the transaction, the director now owns 18,282 shares of the company’s stock, valued at approximately $17,953,838.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bonnie L. Bassler sold 854 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $979.25, for a total value of $836,279.50. Following the completion of the sale, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,353,323.50. The disclosure for this sale can be found here. Insiders sold a total of 10,095 shares of company stock worth $9,664,476 in the last three months. 8.83% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages have issued reports on REGN. Truist Financial reaffirmed a “buy” rating and set a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Bank of America lifted their target price on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research report on Friday, April 12th. BMO Capital Markets boosted their price objective on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a research note on Monday, February 5th. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Finally, Barclays raised their price objective on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 23rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $977.77.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.